Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

Archives of Neurology

Volumn 58, Issue 3, 2001, Pages 417-422

  Farlow, M R ^a   Hake, A ^a   Messina, J ^a   Hartman, R ^a   Veach, J ^a   Anand, R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

EID: 0035106966     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.3.417     Document Type: Article

References (26)

1. Molecular genetics of Alzheimer's disease
2. Incidence of dementia in a population older than 75 years in the United Kingdom
3. Rate of progression of Alzheimer's disease is associated with genetic risk
4. The prognosis in Alzheimer's disease: "How far" rather than "how fast" best predicts the course
5. Rapidly progressive Alzheimer's disease
6. Natural history of Alzheimer's disease and other dementias: Review of the literature in the light of findings from the Kungsholmen project
7. Assessment of progression and prognosis in "possible" and "probable" Alzheimer's disease
8. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part IV: Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
9. "How far" vs "how fast" in Alzheimer's disease: The question revisited
10. A new rating scale for Alzheimer's disease
11. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician
12. The Global Deterioration Scale for assessment of primary degenerative dementia
13. Measurement of quality-of-life changes in patients with Alzheimer's disease
14. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
15. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity
16. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease
17. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Aizheimer's disease: Results of a Canadian double-blind, crossover, multicenter study
18. Severity of Alzheimer's disease and response to cholinergic therapy
19. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
20. A randomized trial evaluating efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
21. A longitudinal study of Alzheimer's disease measurement, rate and predictors of cognitive deterioration
22. Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer's disease
23. Development of aphasia, apraxia and agnosia and decline in Alzheimer's disease
24. Extrapyramidal signs in patients with Alzheimer's disease
25. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease